1.    Rozzanigo, U. et al. Chemoembolization with Degradable Starch Microspheres (DSM-TACE). Expanding indications in HCC multidisciplinary tumor board. Hepatoma Research 9, 14; 10.20517/2394-5079.2022.66 (2023).

2.    Lucatelli, P. et al. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 44, 1851–1867; 10.1007/s00270-021-02968-1 (2021).

3.    Auer, T. A. et al. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. Acta Radiol 62, 313–321; 10.1177/0284185120926474 (2021).

4.    Ludwig, J. M. et al. European Multicenter Study on Degradable Starch Microsphere TACE. The Digestible Way to Conquer HCC in Patients with High Tumor Burden. Cancers 13, 5122 (2021).

5.    Orlacchio, A. et al. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC). Long-term results from a single-center 137-patient cohort prospective study. Radiol Med, 98–106; 10.1007/s11547-019-01093-x (2020).

6.    Minici, R. et al. Safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization as a bridging therapy in patients with early stage hepatocellular carcinoma and Child-Pugh stage B eligible for liver transplant. Front. Pharmacol. 12, 634084; 10.3389/fphar.2021.634084 (2021a).

7.    Vogl, T. J. et al. Transarterial chemoembolization of colorectal cancer liver metastasis. Improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol 31, 2242–2251; 10.1007/s00330-020-07253-2 (2021).

8.    Goerg, F. et al. Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma. A Pilot Study. Cardiovasc Intervent Radiol; 10.1007/s00270-019-02344-0 (2019).

9.    Vogl, T. J. et al. Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases. European radiology; 10.1007/s00330-018-5757-8 (2019).

Concerns EmboCept ® S, manufactured by Serumwerk Bernburg AG